retatrutide phase 2 trial new england journal of medicine for Obesity Retatrutide Phase 3: 60% Achieved

Rybelsus stands apart as an oral tablet, offering an attractive option for individuals who may have reservations about injections

In a substudy of 178 patients from the SUSTAIN 8 trial on semaglutide as a diabetes treatment, the average proportion of lean mass loss was nearly identical at 40%, despite lower doses and less total weight loss than in the STEP 1 trial

Intervening during this stage by combining GLP-1RAs with established therapeutic strategies could theoretically provide a dual benefit by simultaneously modulating immune activation and correcting metabolic dysfunction, with the potential to prevent or delay disease progression

The main difference is the glucagon component in retatrutide, which can produce more noticeable energy shifts and temperature changes in the first 24 hours

They had a reduction in HbA1c from 67 to 60 mmol/mol